Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

财中社1月16日电 恒瑞医药（600276）（600276）发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司和上海恒瑞医药有限公司获得国家药品监督管理局核准签发的注射用SHR-A1811和注射用SHR-9839的药物临床试验批准通知书，将于近期开展相关临床试验。注射用SHR-A1811将进行ⅠB/Ⅱ期临床研究，主要用于晚期实体瘤患者的安全性、耐受性及有效性评估。 注射用SHR-A1811的研发 ...

2025年1月16日，江苏恒瑞医药股份有限公司（证券代码：600276，证券简称：恒瑞医药）宣布，其子公司苏州盛迪亚生物医药有限公司和上海恒瑞医药有限公司收到国家药品监督管理局（国家药监局）核准签发的关于注射用SHR-A1811和注射用SHR-9839的《药物临床试验批准通知书》，并计划于近期开展临床试验。注射用SHR-A1811是一种 ...

Enliven's initial phase 1 data for ELVN-001 in CML shows promising tolerability and activity in heavily pretreated patients. But read why ELVN stock is a Sell.

Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...

YL211 is currently in a Phase I study for patients with advanced solid tumors with a primary completion date of April 2027. Roche also has two FDA-approved ADCs: Polivy and Kadcyla. Polivy came ...

INR:3002. best rtp slots on stake AZ, Novartis, and Bayer are competing for the market! The market of over 26 million patients will usher in a big explosi ...

经查询，目前国外已上市的同类产品有Ado-trastuzumab emtansine（商品名Kadcyla）和Fam-trastuzumab deruxtecan（商品名Enhertu）。Kadcyla由罗氏公司开发，2019年国内 ...

The price you pay for Kadcyla may depend on several factors. These include your dosage and whether you have health insurance. Financial assistance may be available to help with Kadcyla’s cost.